REGENXBIO: Savvy Acquisition By Management And Plenty Of Irons In The Fire

Shares of REGENXBIO (RGNX) have risen by roughly 50% since I first presented the company as an early stage gene therapy pioneer worthy of consideration. In late March I recommended investors buy shares on weakness and just a couple months later there was a decent dip to take advantage of.

ChartRGNX data by YCharts

Keys to the investing thesis included the following:

READ FULL ARTICLE HERE

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.

Baltimore Business Spotlight

Feature Your Business Here

Connect with these Baltimore Professionals on LinkedIn

  • Edwin Warfield

    Editor in Chief, Warfield Digital

    Connect
  • Jean Halle

    Independent Consultant

    Connect
  • Larry Lichtenauer

    President of Lawrence Howard & Associates

    Connect
  • Newt Fowler

    Partner at Womble Carlyle, LLP

    Connect
  • David Crowley

    Owner at Develop DC

    Connect
  • Carolyn Stinson

    Stinson Marketing Group

    Connect